HomeComparePKBO vs QYLD

PKBO vs QYLD: Dividend Comparison 2026

PKBO yields 8888.89% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PKBO wins by $17290949737713800.00M in total portfolio value
10 years
PKBO
PKBO
● Live price
8888.89%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17290949737713800.00M
Annual income
$16,916,578,202,775,594,000,000.00
Full PKBO calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — PKBO vs QYLD

📍 PKBO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPKBOQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PKBO + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PKBO pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PKBO
Annual income on $10K today (after 15% tax)
$755,555.56/yr
After 10yr DRIP, annual income (after tax)
$14,379,091,472,359,256,000,000.00/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, PKBO beats the other by $14,379,091,472,359,256,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PKBO + QYLD for your $10,000?

PKBO: 50%QYLD: 50%
100% QYLD50/50100% PKBO
Portfolio after 10yr
$8645474868856900.00M
Annual income
$8,458,289,101,387,797,000,000.00/yr
Blended yield
97.83%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PKBO buys
0
QYLD buys
0
No recent congressional trades found for PKBO or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPKBOQYLD
Forward yield8888.89%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$17290949737713800.00M$25.4K
Annual income after 10y$16,916,578,202,775,594,000,000.00$5,659.31
Total dividends collected$17265985963886318.00M$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: PKBO vs QYLD ($10,000, DRIP)

YearPKBO PortfolioPKBO Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$899,589$888,888.89$10,352$1,192.36+$889.2KPKBO
2$75,694,763$74,732,202.61$10,830$1,347.57+$75.68MPKBO
3$5,957,858,933$5,876,865,536.53$11,460$1,539.07+$5957.85MPKBO
4$438,676,028,838$432,301,119,780.33$12,275$1,777.84+$438676.02MPKBO
5$30,217,280,421,144$29,747,897,070,286.80$13,323$2,078.95+$30217280.41MPKBO
6$1,947,399,451,993,550$1,915,066,961,942,926.00$14,667$2,463.34+$1947399451.98MPKBO
7$117,429,004,658,116,600$115,345,287,244,483,520.00$16,396$2,960.57+$117429004658.10MPKBO
8$6,625,994,131,926,989,000$6,500,345,096,942,805,000.00$18,631$3,612.97+$6625994131926.97MPKBO
9$349,879,939,194,586,330,000$342,790,125,473,424,500,000.00$21,548$4,482.15+$349879939194586.31MPKBO
10$17,290,949,737,713,800,000,000$16,916,578,202,775,594,000,000.00$25,398$5,659.31+$17290949737713800.00MPKBO

PKBO vs QYLD: Complete Analysis 2026

PKBOStock

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.

Full PKBO Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this PKBO vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PKBO vs SCHDPKBO vs JEPIPKBO vs OPKBO vs KOPKBO vs MAINPKBO vs XYLDPKBO vs JEPQPKBO vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.